These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29171139)

  • 21. Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.
    Retlich S; Duval V; Graefe-Mody U; Friedrich C; Patel S; Jaehde U; Staab A
    Clin Pharmacokinet; 2015 Jul; 54(7):737-50. PubMed ID: 25637172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA).
    Christensen AS; Hædersdal S; Støy J; Storgaard H; Kampmann U; Forman JL; Seghieri M; Holst JJ; Hansen T; Knop FK; Vilsbøll T
    Diabetes Care; 2020 Sep; 43(9):2025-2033. PubMed ID: 32661107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
    Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
    Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
    Rhee EJ; Lee WY; Yoon KH; Yoo SJ; Lee IK; Baik SH; Kim YK; Lee MK; Park KS; Park JY; Cha BS; Lee HW; Min KW; Bae HY; Kim MJ; Kim JA; Kim DK; Kim SW
    Diabetes Obes Metab; 2010 Dec; 12(12):1113-9. PubMed ID: 20977584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis.
    Zeng Z; Choi DS; Mohan V; Emser A; Siddiqui K; Gong Y; Patel S; Woerle HJ
    Curr Med Res Opin; 2015 Jan; 31(1):99-106. PubMed ID: 25215428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.
    Giorda CB; Cioffi G; Lucci D; Nada E; Ognibeni F; Mancusi C; Latini R; Maggioni AP;
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):547-555. PubMed ID: 31418140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.
    Inagaki N; Onouchi H; Sano H; Funao N; Kuroda S; Kaku K
    Lancet Diabetes Endocrinol; 2014 Feb; 2(2):125-32. PubMed ID: 24622716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus.
    Tadayasu Y; Sarashina A; Tsuda Y; Tatami S; Friedrich C; Retlich S; Staab A; Takano M
    J Pharm Pharm Sci; 2013; 16(5):708-21. PubMed ID: 24393553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials.
    Kanasaki K; Qu S; Yamamoto F; Schepers C; Sani Simões R; Yabe D; Ji L
    Expert Opin Drug Saf; 2022 Mar; 21(3):425-434. PubMed ID: 34711126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes.
    Chong SC; Sukor N; Robert SA; Ng KF; Kamaruddin NA
    Front Endocrinol (Lausanne); 2022; 13():1012412. PubMed ID: 36267570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
    Friedrich C; Glund S; Lionetti D; Kissling CJ; Righetti J; Patel S; Graefe-Mody U; Retlich S; Woerle HJ
    Br J Clin Pharmacol; 2013 Sep; 76(3):445-54. PubMed ID: 23331248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study).
    Kim G; Lim S; Kwon HS; Park IB; Ahn KJ; Park CY; Kwon SK; Kim HS; Park SW; Kim SG; Moon MK; Kim ES; Chung CH; Park KS; Kim M; Chung DJ; Lee CB; Kim TH; Lee MK
    Diabetes Obes Metab; 2020 Sep; 22(9):1527-1536. PubMed ID: 32319168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
    Groop PH; Cooper ME; Perkovic V; Sharma K; Schernthaner G; Haneda M; Hocher B; Gordat M; Cescutti J; Woerle HJ; von Eynatten M
    Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials.
    Del Prato S; Patel S; Crowe S; von Eynatten M
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):886-92. PubMed ID: 27484756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.
    Muskiet MHA; Tonneijck L; Smits MM; Kramer MHH; Ouwens DM; Hartmann B; Holst JJ; Danser AHJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2022 Jan; 24(1):115-124. PubMed ID: 34580975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
    Lee SH; Gantz I; Round E; Latham M; O'Neill EA; Ceesay P; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    BMC Endocr Disord; 2017 Nov; 17(1):70. PubMed ID: 29110647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.
    Del Prato S; Barnett AH; Huisman H; Neubacher D; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2011 Mar; 13(3):258-67. PubMed ID: 21205122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.